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adjuvant given on an identical time sched-
ule. Information on potentially modifying 
underlying renal and concomitant diseases 
is not provided. After 42 months of follow-
up, the AS04-based HBsAG vaccine elic-
ited signiﬁcantly greater immunogenicity 
(immune response following antigen 
exposure), as shown by the higher rate of 
patients having anti-HBsAG titers higher 
than 10 mIU/ml (78% versus 51%) and 
100 mIU/ml (54% versus 29%) and fewer 
patients requiring booster doses (43% ver-
sus 17%).8 Furthermore, a booster dose 
with HBV-AS04 was shown to be highly 
eﬀective when given to all patients remain-
ing after 42 months irrespective of their 
previous vaccination group. Reactogenicity 
(adverse events following vaccination), on 
the other hand, was increased as well with 
the novel AS04 vaccine but remained in an 
acceptable range.8
The report by Kong et al.8 reveals that in 
addition to dose and number of pathogen 
inoculation, the coadministered adjuvant 
can be much more critical for enhanced 
vaccine immunogenicity than previously 
expected. The AS04 adjuvant utilized 
monophosphoryl lipid A, a derivative of 
the active moiety of bacterial lipopoly-
saccharide.9 Monophosphoryl lipid A is 
thought to act as an agonist on Toll-like 
receptor-4 and thereby links the innate 
immune system to the adaptive immune 
response, that is, antibody production by 
B cells.9,10 Figure 1 provides a schematic 
model showing how vaccine pathogen and 
adjuvant may interact with endogenous 
immune cells to produce immunogenicity. 
Further, even more promising new vac-
cine adjuvants, such as small oligodeoxy-
nucleotide ligands to Toll-like receptor-9, 
are already in clinical testing.9,10 Whether 
these new vaccine adjuvants may act as 
well through other innate pathogen-rec-
ognition receptors or even other pathways 
is currently debated.9,10
In conclusion, prevention of hepatitis 
B infection and disease in patients with 
advanced or end-stage renal disease has 
largely improved over the recent decades. 
HBsAG vaccination dose, adjuvant, and 
time schedule have been adapted, intensi-
ﬁed, and tailored for this population. How-
ever, there is still a substantial gap to close 
for suﬃcient prevention of HBV infection 
and disease. Until more eﬀective vaccines 
are available, we feel that HBV vaccination 
should be considered even at early stages of 
chronic kidney disease (CKD) and imple-
mented as a standard routine vaccination 
starting in patients at CKD stage 3. HBV 
vaccination is safe and eﬀective and has 
become an integral part of many stand-
ard immunization programs worldwide. 
CKD stage 3 patients are clearly at risk for 
becoming dialysis-dependent and in most 
cases are not yet immune-compromised. 
Implementation of HBV vaccination strat-
egy as early as CKD stage 3 would mark-
edly bolster our attempts to prevent HBV 
infection and disease in patients with more 
advanced or end-stage renal failure.
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Acute kidney injury (AKI) has a strong 
impact on morbidity, mortality, and 
resource utilization regardless of the 
etiology, setting, or definition used. 
Unfortunately, there are virtually no 
therapies to reverse AKI. Those applied 
late in the course of the injury, after an 
obvious increase in serum creatinine, 
have proven ineffective. Thus, recent 
efforts have focused on the identifi-
cation of early-detection markers of 
AKI, at a critical time when the con-
dition may be responsive to interven-
tion. Over 20 unique serum and urine 
biomarkers have now been reported in 
the past 7 years,1 fueled by advances 
in biotechnology and bioinformatics. 
Han et al.2 (this issue) describe three 
urinary biomarkers: kidney injury 
molecule-1, N-acetyl-β-d-glucosami-
nidase, and matrix metalloproteinase-9. 
Will these promising biomarkers trans-
late into widespread clinical use like car-
diac troponin? Or will they prove less 
than ideal when evaluated in broader 
testing, as in other clinical settings?3,4 
What fundamental epidemiologic con-
cepts need to be considered within a 
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diagnostic, prognostic, screening, and 
therapeutic context before such mark-
ers can be used in clinical care?
Diagnostic and prognostic testing
The diagnostic properties of a biomar-
ker are ﬁrst assessed by comparison of 
its value to some reference standard. 
Although serum creatinine is frequently 
measured in routine care, it is more likely 
that novel biomarkers will be measured 
only after a suspected insult. Thus the 
absolute value, rather than a change in 
value, may be most meaningful for com-
parison with a reference standard. With 
respect to the reference standard, what is 
the appropriate outcome in AKI: is it 25%, 
50%, doubling, or some absolute increase 
in serum creatinine? As described by 
Han et al. in their cross-sectional study,2 
should elevations in creatinine be com-
bined with additional clinical features 
such as urinalysis to distinguish the clini-
cal phenotypes of acute tubular necrosis 
from prerenal azotemia? Also, should the 
biomarker assess early AKI (occurring in 
the ﬁrst 24 hours after an insult) or rela-
tively delayed and sustained AKI (lasting 
longer than 48 hours)?
Alternatively, are clinical events the 
most important reference standard — the 
utility of a biomarker to identify individu-
als at high risk of outcomes such as short- 
and long-term death, need for dialysis, or 
duration of hospitalization?
In truth, all of these reference stand-
ards and outcomes are important, and 
the ideal threshold for a biomarker will 
maximize sensitivity, specificity, and 
other associative measures for most out-
comes. To this end, regulatory guidelines 
to approval of disease-speciﬁc biomar-
kers for AKI and other conditions are 
being actively developed in many coun-
tries. Similar to advances in the ﬁeld of 
oncology, the process of systematically 
moving AKI biomarkers through vari-
ous phases of testing needs to be further 
refined.5 Specifically, steps should be 
taken to minimize bias in the design, con-
duct, analysis, and interpretation of stud-
ies.6 For example, comparisons between 
biomarkers and the reference stand-
ard should be made in an independent 
blinded fashion, where the reference 
standard is assessed in all patients in the 
same way without knowledge of biomar-
ker values. To ascertain relationships with 
most clinically important events, future 
studies will require cohorts of about 5 
to 20 times the size of that of Han et al.2 
to validate promising biomarkers. Such 
eﬀorts should focus on hypothesis test-
ing for only a select number of promising 
biomarkers. At least six biomarkers have 
already been reported within the same 
pediatric cardiac surgery cohort used by 
Han et al.2 (previous reports described 
NGAL, interleukin-18, and L-FABP7,8), 
and some biomarkers were initially 
identified through large-throughput, 
discovery-based methods. As seen with 
high-throughput technology, there may 
be spurious false associations between 
some of these biomarkers and outcome.
Furthermore, interpreting clinical 
information in common real-world 
environments such as the adult inten-
sive care unit is truly a messy business. 
Many tests can distinguish the healthy 
from the severely aﬀected (as also shown 
in the cross-sectional study of Han et 
al.2). Even pediatric cardiac surgery is 
among the cleanest of settings in which 
AKI occurs (nested case-control study of 
Han et al.2). In truth, the pragmatic value 
of new biomarkers will be established by 
replication within samples that include 
Figure 1 | Two clinical-trial designs for biomarker-intervention trials. (a) Randomization 
for biomarker measurement followed by intervention in everyone in whom disease is 
detected. (b) Randomization for intervention after biomarker measurement in all participants. 
(Adapted from ref. 10.)
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the appropriate spectrum of patients to 
whom the diagnostic biomarker will be 
applied. Whether these biomarkers will 
generalize to these other settings, and 
diﬀerentiate early AKI from other target 
disorders, remains to be seen.
Screening and therapeutic considerations
Although new biomarkers may help us 
understand disease processes and predict 
how early AKI will aﬀect our patients, we 
are most interested to know how we can 
use such biomarkers to change the natu-
ral course of otherwise poor outcomes. 
For known predictable insults such as 
cardiac bypass surgery, biomarkers may 
not be needed at all for risk stratiﬁca-
tion, if prophylactic therapy is shown to 
be eﬀective and safe in randomized con-
trolled trials. Arguably, n-acetylcysteine 
and intravenous sodium bicarbonate 
have such a safety proﬁle, and their use 
in such settings is being tested in ongoing 
randomized controlled trials.
One could consider new biomarkers as 
surrogate end points in smaller clinical 
trials, to help identify those interventions 
best suited for additional testing in larger 
studies. Indeed, in most clinical settings 
AKI-associated dialysis and mortality 
remain infrequent events. Because of the 
cost of conducting such trials, only a lim-
ited number of trials with adequate statis-
tical power for such outcomes will ever 
be done. For a biomarker to be valid as a 
surrogate end point, there should be evi-
dence of a strong, independent, and con-
sistent association with clinical outcomes, 
and evidence from randomized control-
led trials that improvement in biomarker 
levels consistently leads to improvement 
in clinical outcomes.9 Unfortunately, this 
then becomes a circular approach. We are 
considering new biomarkers as surrogate 
end points to identify the most promising 
therapies for further testing. However, 
our conﬁdence in using this strategy will 
only be realized after we identify eﬀective 
interventions that improve both biomar-
ker levels and clinical outcomes in large 
clinical trials.
Other biomarkers provide a lead time of 
a few days for the diagnosis of AKI before 
its presence is obvious from other measures 
such as the serum creatinine. If biomarkers 
are used as a screening tool, then it should 
be shown in randomized controlled trials 
that application of interventions earlier in 
the process of AKI is indeed beneﬁcial. 
There are two common designs to test 
the impact of such a screening process10 
(Figure 1). In the first design, patients 
are randomized to have the biomarker 
measured, and anyone with an elevated 
level is treated with the intervention (Fig-
ure 1a). In the second design, all patients 
have the biomarker measured, and those 
with elevated levels are randomized to be 
treated or not with therapy (Figure 1b). In 
other words, the elevated biomarker level 
becomes an inclusion criterion for a clini-
cal trial. Although we prefer the method 
in Figure 1b, in both designs one can con-
clude that the biomarker has identiﬁed a 
group of patients in whom early treatment 
has been beneﬁcial (for example, predicted 
response to therapy) if those who receive 
treatment do better. Conceptually such 
trials may identify some harm associ-
ated with screening, such as side eﬀects of 
treatment in those who have false-positive 
biomarker results. As with all trials, there 
are additional considerations, including 
the cost-eﬀectiveness and resource utili-
zation of biomarker measurement.
In conclusion, there is now unprec-
edented enthusiasm in nephrology for 
early AKI biomarker detection research. 
Advancing patient care will require a 
commitment to all phases of biomarker 
development and testing. This must 
include an awareness of fundamental epi-
demiologic principles, to minimize bias 
and maximize clinical utility.
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